0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

NIH testing sorbinil to prevent diabetic retinopathy

Charles Marwick
JAMA. 1984;252(10):1263. doi:10.1001/jama.1984.03350100005003.
Text Size: A A A
Published online

ABSTRACT

A placebo-controlled trial involving more than 800 patients with type I insulin-dependent diabetes has been started by one of the National Institutes of Health (NIH), Bethesda, Md, to evaluate the use of sorbinil in the prevention of diabetic retinopathy.

The study, which admitted the first subjects in March, is being conducted by the NIH's National Eye Institute. The institute plans to follow up the patients for at least 30 months. The project cost has not been announced, but the study is being supported by Pfizer, Inc, New York City, the developer of sorbinil.

Diabetic retinopathy occurs in about 4.4 million of the estimated 10 million to 11 million persons with diabetes in the United States. Every year, about 4,700 of these patients become blind. Research studies have suggested that sorbinil may help alleviate retinopathy.

Sorbinil is an aldose-reductase inhibitor. Earlier studies on diabetic animals have shown that it can reduce

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();